Felicity Edwards

Dr. Felicity Edwards


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2025 in Journal of Infection
Verified
Journal Article
Open access
ASAdam G. Stewart
Adam G. Stewart
FEFelicity Edwards
Felicity Edwards
FEFelicity Edwards
Felicity Edwards
SKSophia Koo
Sophia Koo
SHSarah P. Hammond
Sarah P. Hammond
SCSharon C.-A. Chen
Sharon C.-A. Chen
The global burden of bloodstream infection (BSI) due to Candida, and species previously classed as Candida (Candida-like species) is substantial. Recent emergence of Candida auris, fluconazole-resistant Candida parapsilosis and echinocandin-resistant Nakaseomyces glabratus emphasise the importance of global and regional surveillance. Blood cultures with growth of Candida/Candida-like species in Queensland, Australia (population ≈ 5 million) over a 20-year period (1 January 2000-31 December 2019) were retrospectively identified. Clinical, microbiological and outcome information was obtained from state-wide databases. Cox proportional and Fine-Gray subdistribution hazard models were used to construct hazard ratios for 30-day all-cause case fatality and 1-year recurrence, respectively. A total of 2586 episodes (2420 patients) of Candida/Candida-like bloodstream infection (Ca-BSI) were identified; 249 episodes (9.5%) were in children. Candida albicans and C. parapsilosis complex reduced in frequency, whilst N. glabratus and Candida dubliniensis increased during the study. Of 1836 isolates tested, fluconazole (3.2%) and echinocandin (0.7%) resistance rates were low, with a decrease in fluconazole resistance observed from the first half of the study period to the latter half (4.5% versus 2.2%, P<0.01). Overall, 30-day all-cause mortality (21%) was unchanged: C. parapsilosis complex (aHR 0.44, 95% CI 0.32-0.60) was associated with decreased mortality, while C. tropicalis (aHR 1.35, 95% CI 0.95-1.93) was associated with an increase. Only 3.1% episodes demonstrated recurrence of Ca-BSI within one year. Presence of uncommon Candida species (aSHR 6.60, 95% CI 2.99-14.56) and an endovascular source of infection (aSHR 4.42, 95% CI 1.87-10.46) were associated with recurrence, while male gender (aSHR 0.57, 95% CI 0.35-0.92) was protective. Resistance to fluconazole (3.2% vs 3.5%, P=0.58) and echinocandins (0.6% vs 2.0%, P=0.05) was higher in recurrent Ca-BSI episodes. Females had a higher rate of fluconazole resistance (4.1% versus 2.4%, P=0.02). Our study highlights important shifts in causative species and resistance patterns of Ca-BSI which impacts clinical management. Antifungal resistance rates were low overall. The identification of new modifiable and non-modifiable risk factors for recurrence and mortality provides opportunities to examine new strategies to improve patient outcomes.

26 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MRMahesh Ramanan
Mahesh Ramanan
ATAlexis Tabah
Alexis Tabah
JAJulia Affleck
Julia Affleck
FEFelicity Edwards
Felicity Edwards
KWKyle C White
Kyle C White
FEFelicity Edwards
Felicity Edwards
Phosphate is a predominately intracellular anion that has several key roles in normal cellular functions. Derangements in serum phosphate concentration occur frequently during critical illness, particularly hypophosphataemia, which has been reported in up to 75% of Intensive Care Unit (ICU) patients. The association between hypophosphataemia and ICU outcomes reported in the literature are conflicting and and subject to substantial confounding. Exogenous phosphate can be administered in the ICU using the enteral and intravenous route safely. However, whether administering phosphate and correcting hypophosphataemia results in any patient-centred benefits, or harms, remains uncertain, particularly for patients with mild hypophosphataemia or low-normal phosphate levels. This review will highlight key aspects of hypophosphataemia management in the critically ill, summarise current best practice, and outline major research priorities.

1 February 2022 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Open access
FEFelicity Edwards
Felicity Edwards
MRMahesh Ramanan
Mahesh Ramanan
KSKiran Shekar
Kiran Shekar
MKMarianne Kirrane
Marianne Kirrane
PCPierre Clement
Pierre Clement
ATAlexis Tabah
Alexis Tabah
Use of death as an outcome of intensive care unit (ICU) admission may be biased by differential discharge decisions. To determine the validity of ICU survival status as an outcome measure of all cause case-fatality. A retrospective cohort of first admissions among adults to four ICUs in North Brisbane, Australia was assembled. Death in ICU (censored at discharge or 30 days) was compared with 30-day overall case-fatality. The 30-day overall case-fatality was 8.1% (2436/29,939). One thousand six hundred and thirty-one deaths occurred within the ICU stay and 576 subsequent during hospital post-ICU discharge within 30-days; ICU and hospital case-fatality rates were 5.4% and 7.4%, respectively. An additional 229 patients died after hospital separation within 30 days of ICU admission of which 110 (48.0%) were transferred to another acute care hospital, 80 (34.9%) discharged home, and 39 (17.0%) transferred to an aged care/chronic care/rehabilitation facility. Patients who died after ICU discharge were older, had higher APACHE III scores, were more likely to be elective surgical patients, and were less likely to be out of state residents or managed in a tertiary referral hospital. Limiting determination of case-fatality to ICU information alone would correctly detect 95% (780/821) of all-cause mortality at day 3, 90% (1093/1213) at day 5, 75% (1524/2019) at day 15, 72% (1592/2244) at day 21, and 67% (1631/2436) at day 30 of follow-up. Use of ICU case-fatality significantly underestimates the true burden and biases assessment of determinants of critical illness-related mortality in our region.

29 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VRVignesh Raman
Vignesh Raman
MRMahesh Ramanan
Mahesh Ramanan
FEFelicity Edwards
Felicity Edwards
FEFelicity Edwards
Felicity Edwards
Amongst critically ill patients managed in the intensive care unit (ICU) setting, disorders of sodium and water balance, or dysnatraemias, are commonly encountered either at time of admission or during ICU stay. There is extensive literature associating both extremities of incident dysnatraemia, hyponatraemia, and hypernatremia, with higher mortality and morbidity amongst a range of ICU disease populations. Therefore, a comprehensive understanding of sodium homeostasis mechanisms, effects of deranged sodium physiology, comprehensive diagnostic workup, and avoidance of suboptimal management are paramount to the critical care clinician. This narrative review incorporated a PubMed search to summarise contemporary literature perspectives of (a) sodium homeostasis mechanisms, (b) descriptions of dysnatraemia, (c) ICU-specific challenges to dysnatraemia diagnosis, (d) associated clinical outcomes in critically ill populations, and (e) ongoing paucity to deranged sodium physiology literature relevant to daily ICU practice. The purpose of this review is to both guide critical care clinicians towards performing a diagnostic approach to dysnatraemia with integrated physiology for a tailored treatment strategy as well as highlight ongoing research priorities in the realm of deranged sodium physiology.

27 April 2023 in Australian Critical Care
Verified
Journal Article
Open access
FEFelicity Edwards
Felicity Edwards
MBMatthew Bright
Matthew Bright
CDClaire Dux
Claire Dux
FCFiona Coyer
Fiona Coyer
FEFelicity Edwards
Felicity Edwards
There is a lack of data surrounding the use of therapeutic caffeine among adults admitted to intensive care units (ICUs). The objective of this study was to determine reported caffeine use and withdrawal symptoms among patients admitted to the ICU to inform future prospective interventional trials. This study used a cross-sectional survey design, where a survey was conducted by a registered dietitian among 100 adult patients admitted to an ICU in Brisbane, Australia. The median age of patients was 59.8 y (interquartile range: 44.0-70.0), and 68% were male. Ninety-nine percent of patients had daily consumption of caffeine with a median 338 mg (interquartile range: 162-504). Caffeine consumption was self-reported in 89% of patients and was uncovered by detailed identification in 10%. Almost one-third (29%) reported caffeine withdrawal symptoms while admitted to intensive care. Common withdrawal symptoms reported were headaches, irritability, fatigue, anxiety, and constipation. Eighty-eight percent of patients reported willingness to participate in future studies of therapeutic caffeine if they were admitted to the ICU. Preferred methods of parenteral and enteral routes of administration varied by patient and illness characteristics. Patients admitted to this ICU were ubiquitous consumers of caffeine before admission, and one-tenth were unaware. Patients viewed trials of therapeutic caffeine as highly acceptable. The results provide important baseline information for future prospective studies.

22 December 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
HSHolly Angela Sinclair
Holly Angela Sinclair
FEFelicity Edwards
Felicity Edwards
PHPatrick Harris
Patrick Harris
CHClaire Heney
Claire Heney
FEFelicity Edwards
Felicity Edwards
Aeromonas species can cause severe bloodstream infection (BSI) however, few studies have examined their epidemiology in non-selected populations. The objective of this study was to describe the incidence and determinants of Aeromonas species BSI in Queensland, Australia. A retrospective population-based cohort study was conducted during 2000–2019. Aeromonas species BSI were identified by laboratory surveillance and clinical and outcome information through data linkages to statewide databases. A total of 407 incident Aeromonas species BSI were identified with an age- and sex-standardized incidence of 5.2 per million residents annually. No trend in annual incidence rate during two decades of surveillance was demonstrated. Significant variable monthly occurrences were observed with highest rates during warmer, wetter months, and lowest rates during winter and dry periods. There was significant variability in incidence accordingly to region and climate zones, with higher rates observed in tropical north regions and lowest in southeastern corner. The highest incidence was observed in very remote and hot areas in Queensland. Cases were infrequent in children and risk was highest in elderly and males. Seventy-eight patients died within 30 days with a case-fatality rate of 19%. Older age, non-focal infection, higher Charlson score, and monomicrobial bacteremia were independent risk factors for death. Demographic and climatic changes may increase the burden of these infections in future years.